Molecular High-Grade B-Cell Lymphoma: Defining a Poor-Risk Group That Requires Different Approaches to Therapy In prostate cancer, end points that reliably portend prognosis and treatment benefit ...
AENEAS: A Randomized Phase III Trial of Aumolertinib Versus Gefitinib as First-Line Therapy for Locally Advanced or MetastaticNon–Small-Cell Lung Cancer With EGFR Exon 19 Deletion or L858R Mutations ...
Charlie Wilson, Jean Fogelberg and Rosey Grier Join “Advance on Washington” to Improve Treatments, Reduce Overtreatment WASHINGTON--(BUSINESS WIRE)-- With $3 billion spent on the over-treatment of ...
Studies have shown that disruptions in circadian rhythms caused by chronic sleep deprivation and other lifestyle-related issues are linked to an increased incidence of some cancers, including prostate ...
Why would any healthy person, newly diagnosed with cancer, elect not to undergo curative treatment? Newly diagnosed prostate cancer patients presented with the option of active surveillance often ask ...
Measuring biochemical recurrence (BCR) as a surrogate marker produces unreliable results as a primary end point for overall survival of patients with localized prostate cancer, a study found. In a ...
As the result of a six-year long research process, Fredrick R. Schumacher, PhD, MPH, a cancer epidemiology researcher at Case Western Reserve University School of Medicine, and an international team ...
Prostate-specific antigen (PSA) is a uniquely valid tumor marker for prostate cancer screening and early detection. 1 The widespread use of serum PSA testing for early prostate cancer detection has ...
September is Prostate Cancer Awareness month. Prostate cancer is cancer that occurs in a man’s prostate — a small walnut-shaped gland that produces the seminal fluid that nourishes and transports ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results